dc.contributor.author | Gue, Ying X. | |
dc.contributor.author | Jeong, Young-Hoon | |
dc.contributor.author | Farag, Mohamed | |
dc.contributor.author | Spinthakis, Nikolaos | |
dc.contributor.author | Gorog, Diana | |
dc.date.accessioned | 2021-05-21T16:30:01Z | |
dc.date.available | 2021-05-21T16:30:01Z | |
dc.date.issued | 2021-03-01 | |
dc.identifier.citation | Gue , Y X , Jeong , Y-H , Farag , M , Spinthakis , N & Gorog , D 2021 , ' Precision treatment in ACS – role of assessing fibrinolysis ' , Journal of Clinical Medicine (JCM) , vol. 10 , no. 5 , 929 . https://doi.org/10.3390/jcm10050929 | |
dc.identifier.issn | 2077-0383 | |
dc.identifier.other | PURE: 24657490 | |
dc.identifier.other | PURE UUID: 9099e8a4-33f2-47fe-9f84-d5c02a2bbac0 | |
dc.identifier.other | Scopus: 85114069576 | |
dc.identifier.uri | http://hdl.handle.net/2299/24521 | |
dc.description | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | |
dc.description.abstract | Despite advancements in pharmacotherapy and interventional strategies, patients with acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an enhanced tendency to thrombus formation, impairment in the ability to naturally dissolve or lyse a developing thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part of this residual risk regardless of optimal antiplatelet medication. Global assessment of endogenous fibrinolysis, including a point-of-care assay, can identify patients with ACS at persistent high cardiovascular risk and might play an important role in allowing the personalisation of potent antithrombotic therapy to enhance fibrinolytic status, providing precision treatment of ACS to improve long-term outcome. | en |
dc.format.extent | 8 | |
dc.language.iso | eng | |
dc.relation.ispartof | Journal of Clinical Medicine (JCM) | |
dc.title | Precision treatment in ACS – role of assessing fibrinolysis | en |
dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
dc.contributor.institution | Basic and Clinical Science Unit | |
dc.contributor.institution | Centre for Health Services and Clinical Research | |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.description.status | Peer reviewed | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | https://doi.org/10.3390/jcm10050929 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |